In the current study, we demonstrate the efficacy of AAV1.NT-3 gene therapy in the Sh3tc2−/− mouse model of CMT4C leading to significant functional, electrophysiological and histological improvements. This evidence concerns the gene NTF3 and Charcot-Marie-Tooth disease type 4C.